Johnson & Johnson (NYSE:JNJ) Shares Sold by Scott & Selber Inc.

Scott & Selber Inc. lessened its stake in Johnson & Johnson (NYSE:JNJGet Rating) by 1.2% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 15,923 shares of the company’s stock after selling 200 shares during the quarter. Johnson & Johnson comprises approximately 1.1% of Scott & Selber Inc.’s holdings, making the stock its 28th biggest holding. Scott & Selber Inc.’s holdings in Johnson & Johnson were worth $2,822,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in the stock. Family CFO Inc acquired a new position in shares of Johnson & Johnson during the 4th quarter valued at $26,000. Steward Financial Group LLC acquired a new position in shares of Johnson & Johnson during the 4th quarter valued at $34,000. Joseph P. Lucia & Associates LLC acquired a new position in shares of Johnson & Johnson during the 1st quarter valued at $38,000. Advocacy Wealth Management Services LLC lifted its holdings in shares of Johnson & Johnson by 41.4% during the 1st quarter. Advocacy Wealth Management Services LLC now owns 229 shares of the company’s stock valued at $41,000 after acquiring an additional 67 shares in the last quarter. Finally, Gibson Wealth Advisors LLC acquired a new position in shares of Johnson & Johnson during the 4th quarter valued at $49,000. Institutional investors and hedge funds own 68.78% of the company’s stock.

Insiders Place Their Bets

In other news, CAO Robert J. Decker sold 8,462 shares of the company’s stock in a transaction that occurred on Thursday, May 26th. The shares were sold at an average price of $180.00, for a total value of $1,523,160.00. Following the completion of the sale, the chief accounting officer now directly owns 15,473 shares of the company’s stock, valued at approximately $2,785,140. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. In other news, CAO Robert J. Decker sold 8,462 shares of the company’s stock in a transaction that occurred on Thursday, May 26th. The shares were sold at an average price of $180.00, for a total value of $1,523,160.00. Following the completion of the sale, the chief accounting officer now directly owns 15,473 shares of the company’s stock, valued at approximately $2,785,140. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Kathryn E. Wengel sold 40,000 shares of the company’s stock in a transaction that occurred on Friday, June 10th. The stock was sold at an average price of $173.00, for a total transaction of $6,920,000.00. Following the completion of the sale, the executive vice president now directly owns 71,311 shares of the company’s stock, valued at $12,336,803. The disclosure for this sale can be found here. 0.35% of the stock is owned by insiders.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on JNJ shares. Morgan Stanley lifted their target price on shares of Johnson & Johnson from $173.00 to $174.00 and gave the company an “equal weight” rating in a report on Friday, July 8th. The Goldman Sachs Group boosted their price objective on shares of Johnson & Johnson from $163.00 to $181.00 and gave the stock a “neutral” rating in a report on Tuesday, April 12th. Wells Fargo & Company boosted their price objective on shares of Johnson & Johnson from $190.00 to $195.00 and gave the stock an “overweight” rating in a report on Wednesday, July 13th. Credit Suisse Group boosted their price objective on shares of Johnson & Johnson from $200.00 to $205.00 and gave the stock an “outperform” rating in a report on Wednesday, April 20th. Finally, StockNews.com upgraded shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Tuesday, May 17th. Four investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $189.89.

Johnson & Johnson Price Performance

Shares of NYSE:JNJ opened at $173.91 on Tuesday. The company has a quick ratio of 1.14, a current ratio of 1.39 and a debt-to-equity ratio of 0.39. Johnson & Johnson has a fifty-two week low of $155.72 and a fifty-two week high of $186.69. The firm has a 50-day simple moving average of $175.84 and a 200 day simple moving average of $174.50. The company has a market cap of $457.63 billion, a PE ratio of 25.31, a P/E/G ratio of 3.32 and a beta of 0.59.

Johnson & Johnson (NYSE:JNJGet Rating) last posted its earnings results on Tuesday, July 19th. The company reported $2.59 EPS for the quarter, topping the consensus estimate of $2.57 by $0.02. Johnson & Johnson had a net margin of 19.21% and a return on equity of 36.56%. The firm had revenue of $24.02 billion during the quarter, compared to analysts’ expectations of $23.85 billion. During the same quarter in the prior year, the firm earned $2.48 EPS. Johnson & Johnson’s quarterly revenue was up 3.0% on a year-over-year basis. On average, sell-side analysts anticipate that Johnson & Johnson will post 10.05 EPS for the current year.

Johnson & Johnson Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 6th. Shareholders of record on Tuesday, August 23rd will be given a $1.13 dividend. This represents a $4.52 annualized dividend and a yield of 2.60%. The ex-dividend date of this dividend is Monday, August 22nd. Johnson & Johnson’s dividend payout ratio (DPR) is 65.79%.

About Johnson & Johnson

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

See Also

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.